Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Accelrys Transforms Lab-to-Commercialization Process With New Integrated Accelrys Process Management And Compliance Suite

Stock quotes in this article: ACCL 

SAN DIEGO, Sept. 18, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, today announced the new integrated Accelrys Process Management and Compliance Suite of software products designed specifically to enhance product and process insight, facilitate collaboration and streamline product development from research through late-stage quality control and manufacturing. By improving the way businesses manage the scientific innovation lifecycle, the suite helps bring products to market faster and at a lower cost, while meeting critical quality and regulatory compliance objectives.

To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/accelrys-transforms-lab-to-commercialization-process-with-new-integrated-accelrys-process-management-and-compliance-suite-170108246.html

"Companies that rely on science to innovate continue to struggle with quickly and cost-effectively transforming good ideas into successful products," said Accelrys president and chief executive officer Max Carnecchia. "The unified approach to product development and process execution offered by the Accelrys Process Management and Compliance Suite provides a transformative path forward for organizations demanding new ways to accelerate innovation and retain competitive advantages."

The Accelrys Process Management and Compliance Suite directly integrates with systems critical to development and manufacturing processes such as laboratory information management systems (LIMS), enterprise resource planning (ERP), product lifecycle management (PLM) and manufacturing execution systems (MES). The ability to leverage existing applications and infrastructure, combined with the features of the Accelrys Process Management and Compliance Suite, offers organizations for the first time a single, unified source for harmonizing critical-path data and meeting the "right-first-time" needs of downstream manufacturing. The insights gained from the suite enhance reporting, decision making, knowledge management and operational excellence from lab to commercialization.

The Accelrys Process Management and Compliance Suite is the result of Accelrys' 2012 acquisition of VelQuest Corporation with its industry-leading paperless lab execution and data capture technology. The integrated suite comprises:

"For too long lab-to-market value chain processes have been managed by an outmoded combination of disconnected point solutions, paper notebooks and home-grown tools, creating a productivity gap that has slowed innovation," said Ken Rapp, managing director of Accelrys' analytical, development, quality and manufacturing solutions. "The Accelrys Process Management and Compliance Suite changes that paradigm. By combining the capabilities of an electronic lab notebook, lab execution system and an enterprise scientific informatics platform, Accelrys brings a holistic approach to solving common and costly operational challenges ranging from production quality issues and regulatory violations to shrinking margins."

Integration of the Accelrys Process Management and Compliance Suite with the Accelrys Enterprise Platform enables lifecycle aggregation, analytics and comprehensive reporting across the continuum from discovery to manufacturing, supporting Six Sigma and Quality by Design (QbD) programs and International Conference on Harmonization (ICH) initiatives in pharmacovigilance and risk management.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,346.09 -8.31 -0.05%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.930% -0.019

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs